Addition of Levetiracetam May Improve Survival for Glioblastoma
the Cancer Therapy Advisor take:
Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy, a recent study published online in the journal Cancer has shown.
For the study, researchers identified 103 patients with primary glioblastoma who received comcomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide. Of those, 56% received levetiracetam during temozolomide chemotherapy for at least 3 months.
Results showed that median progression-free survival was 9.4 months (95% CI: 7.5-11.3) among those who took levetiracetam compared with 6.7 months (95% CI: 5.8-7.6) among those who did not receive the drug (P = 0.010). Median overall survival was 25.7 (95% CI: 21.7-29.7) and 16.7 months (95% CI: 12.1-21.3), respectively (P = 0.027).
The findings suggest that levetiracetam may improve survival in this patient population, but the authors note that a randomized study is warranted.
Previous studies have suggested the chemosensitizing effect of levetiracetam, an antiepileptic drug, but data surrounding survival benefit is lacking.
Levetiracetam may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer